Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of November 2018, with a report date of November 14, 2018. The filing primarily announces significant changes to the Company's corporate governance and executive leadership.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and contains no financial statements or performance data.
Material Changes
The material changes reported in this filing are organizational:
- Board Appointment: Professor Oded Shoseyov was appointed to the Board of Directors effective November 13, 2018. He is a renowned scientist in plant molecular biology and nano-biotechnology, a faculty member at the Hebrew University of Jerusalem, and the scientific founder of 12 companies.
- Executive Appointment: Dr. Eyal Emmanuel was appointed as Vice President of Corporate Strategy. Dr. Emmanuel previously held R&D positions at Evogene (2006–2017) and served as CTO of the Agrinnovation fund at Yissum Research and Development Company (2017–2018).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, management commentary on business performance, or specific risk factors. The appointment of Professor Shoseyov is noted to be effective until the next general meeting of shareholders, at which time he may be nominated for reelection.
Key Facts for Investor Verification
- Verify the effective date of Professor Oded Shoseyov's board appointment (November 13, 2018).
- Confirm Dr. Eyal Emmanuel's new role as VP of Corporate Strategy and his prior tenure at Evogene.
- Note that this filing contains no financial data; investors should refer to the most recent Form 20-F or quarterly reports for financial performance.